Saturday 17 October 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024. In the quarter to June 2026, revenue grew 10.6%, EPS grew 25.0% and free cash flow grew 557.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

62.11 0.72 −1.15%

Follow EXEL

Alert me

Market cap: $15.6B
P/E: 18.8×
Fwd P/E: 16.7×
Dividend yield: —
F-score: 7/9
Altman Z: 12.68
Beneish M: −2.61
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.19

Total sells 42.24

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	4	—	—	9	—	—	7	2	—	1	—	—

Insider Ownership 4.39%

Capital & Financial Ratios $m

Market Cap 15,570.00

Revenue 2,435.92

Net Income 860.62

Free Cash Flow 1,158.19

Net Debt (839.38)

Current Ratio 3.46

Debt/Equity 0.00

P/E ratio 18.82

Fwd P/E 16.70

P/S ratio 6.40

P/B ratio 8.45

Past 5Y EPS Growth 51.35%

This Y EPS Growth 14.76%

Next Y EPS Growth 16.25%

Next Y revenue growth 10.08%

Next 5Y EPS Growth 19.22%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 37.23%

10-year low 10-year high

P/S against its own 10 years 55.55%

10-year low 10-year high

P/B against its own 10 years 82.53%

10-year low 10-year high

EV/Sales against its own 10 years 63.51%

10-year low 10-year high

EV/FCF against its own 10 years 21.79%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	995	1,111	1,059	839
Receivables	237	265	287	322
Inventory	17	22	22	29
Other	—	—	—	—
	1,318	1,468	1,443	1,251

	2023	2024	2025	Q'26
Payables	34	38	30	39
ST’ Debt	—	—	—	—
Other	108	95	125	103
	394	404	406	362

Compound Annual Growth %

	10y	5y	3y
Sales	51.19%	18.63%	12.93%
Cash Flow	0.00%	33.44%	34.60%
Earnings	0.00%	47.58%	62.53%
Book Value	0.00%	2.84%	(4.59%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	611	629	—	—	—
’25	555	568	598	599	2,320
’24	425	637	540	567	2,169
’23	409	470	472	480	1,830
’22	356	419	412	424	1,611
’21	270	385	328	451	1,435
’20	227	259	231	270	988

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	252	308	—	—	—
’25	211	49	290	334	884
’24	69	120	271	240	700
’23	84	121	117	11	333
’22	148	31	110	74	363
’21	40	182	83	96	401
’20	56	102	18	33	209

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	250	298	—	—	—
’25	189	45	284	326	844
’24	51	95	262	226	634
’23	36	114	23	(3)	170
’22	142	19	102	(39)	224
’21	26	161	69	80	337
’20	53	95	12	19	179

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.79	0.82	—	—	—
’25	0.55	0.65	0.69	0.88	2.78
’24	0.12	0.77	0.40	0.48	1.76
’23	0.12	0.25	0.00	0.27	0.65
’22	0.21	0.22	0.23	(0.09)	0.56
’21	0.01	0.30	0.12	0.29	0.72
’20	0.15	0.21	(0.10)	0.09	0.35

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3.55	14.22	13.42	15.02	13.67	15.50	14.87	16.03	19.20	31.90	Analyst estimates 2026–2028 Powerpack
	High	18.29	32.50	32.20	25.31	27.80	25.77	23.40	24.23	36.97	49.62
People
People	Employees	287	372	484	617	773	954	1,223	1,310	1,147	1,077
	Revenue/emp, $m	0.67	1.22	1.76	1.57	1.28	1.50	1.32	1.40	1.89	2.15
Income, $m
Income, $m	Revenue	191	452	854	968	988	1,435	1,611	1,830	2,169	2,320
	Gross margin, %	96.58	96.67	96.91	96.58	96.33	96.32	96.41	96.04	96.49	96.39
	EBT	(70)	159	452	398	131	294	234	258	682	941
	EBT margin, %	(36.68)	35.05	52.95	41.14	13.25	20.50	14.55	14.07	31.43	40.57
	Net income	(70)	154	690	321	112	231	182	208	521	783
	Depreciation	9	1	5	8	9	14	21	26	29	29
Per share, $
Per share, $	Revenue	0.76	1.54	2.87	3.20	3.20	4.56	5.01	5.75	7.48	8.54
	Earnings	(0.28)	0.52	2.32	1.06	0.36	0.73	0.57	0.65	1.80	2.88
	Cash flow	0.84	0.56	1.40	1.74	0.68	1.27	1.13	1.05	2.41	3.26
	Capex	(0.01)	(0.07)	(0.11)	(0.04)	(0.10)	(0.20)	(0.43)	(0.51)	(0.23)	(0.15)
	Free cash flow	0.83	0.49	1.28	1.70	0.58	1.07	0.70	0.54	2.19	3.11
	Book value	0.36	0.97	4.32	5.57	6.10	7.02	7.74	7.12	7.74	7.96
	Shares, m	251	294	298	303	308	315	322	318	290	272
Valuation, ×
Valuation, ×	P/E	0.00	59.25	8.55	16.62	54.24	24.87	28.60	36.63	18.50	15.17
	P/S	19.28	20.37	6.86	5.51	6.27	4.01	3.25	4.16	4.45	5.13
	P/B	41.32	32.35	4.55	3.16	3.29	2.60	2.11	3.36	4.30	5.51
	EV/Sales	17.51	19.55	6.06	4.65	5.07	3.01	2.46	3.63	3.95	4.68
	EV/FCF	16.05	61.16	13.53	8.76	28.01	12.81	17.65	38.99	13.52	12.87
Cash, $m
Cash, $m	Operating cash flow	210	166	416	527	209	401	363	333	700	884
	Capex	(2)	(21)	(33)	(13)	(30)	(64)	(138)	(163)	(66)	(40)
	Free cash flow	209	145	383	514	179	337	224	170	634	844
Balance, $m
Balance, $m	Working capital	200	370	792	868	1,241	1,497	1,294	924	1,064	1,038
	Total debt	189	15	12	48	49	51	190	—	—	—
	Net debt	(420)	(373)	(693)	(852)	(1,207)	(1,467)	(1,308)	(995)	(1,111)	(1,059)
	Shareholders’ equity	89	285	1,287	1,686	1,879	2,211	2,488	2,264	2,244	2,161
Returns, %
Returns, %	ROA	(15.13)	24.66	66.43	19.41	5.56	9.72	6.41	6.91	17.70	27.02
	ROIC	0.00	0.00	46.17	27.70	10.23	24.10	10.67	8.42	33.35	49.46
	ROE	272.77	82.41	87.77	21.59	6.27	11.30	7.76	8.74	23.13	35.53

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
INSM Insmed, Inc.	$21.7B	— (loss-making)	— (loss-making)	+296.11% (above 0%: growing)	n/m	+54.52% (above 0%: growing)	84.20%	(0.36%)	Compare
EXEL Exelixis, Inc.	$15.6B	18.8×	16.7×	+10.63% (above 0%: growing)	+25.00% (above 0%: growing)	+557.25% (above 0%: growing)	96.71%	39.51%
ASND Ascendis Pharma A/S	$14.9B	16.3×	13.0×	+119.88% (above 0%: growing)	n/m	+2,335.93% (above 0%: growing)	91.85%	64.98%	Compare
JAZZ Jazz Pharmaceuticals PLC	$13.9B	13.8×	17.3×	+15.55% (above 0%: growing)	n/m	+140.99% (above 0%: growing)	90.37%	20.54%	Compare
HALO Halozyme Therapeutics, Inc.	$13.8B	34.6×	10.6×	+47.67% (above 0%: growing)	+44.12% (above 0%: growing)	+141.18% (above 0%: growing)	83.54%	59.80%	Compare
BBIO BridgeBio Pharma, Inc.	$13.1B	— (loss-making)	— (loss-making)	+120.39% (above 0%: growing)	n/m	+16.59% (above 0%: growing)	93.83%	(43.94%)	Compare
CORT Corcept Therapeutics Incorporated	$12.3B	212×	139×	+31.74% (above 0%: growing)	+21.21% (above 0%: growing)	−29.89% (below 0%: shrinking)	98.41%	16.12%	Compare
SMMT Summit Therapeutics PLC	$12.3B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−112.80% (below 0%: shrinking)	0.00%	0.00%	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%	Compare
Median of peers	$13.5B	34.6×	17.3×	+39.71%	—	+35.56%	87.28%	18.33%

All 614 Biotechnology stocks →

Exelixis, Inc. (EXEL) key facts

Strength: Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
Exelixis, Inc. (EXEL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, EXEL traded at $62.11, a market capitalization of $15.6 billion.
Return on equity was 35.5% and debt-to-equity 0.00.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 12.68 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.